Sana Q2 net loss $50.3M ($0.21/sh); cash $251.6M; operating burn target <$200M

Sana Biotechnology, Inc.

2024-Q2 EPS reported -$0.70

Net loss $50.3M ($0.21 per share), improved from $114M loss ($0.59) in Q2 2023.
Cash and equivalents $251.6M; expects 2024 operating cash burn below $200M.
Four clinical trials ongoing across seven indications; initial data expected in 2024 for SC291, SC262, and UP421.
R&D expenses decreased to $60.9M (Q2 2024) from $73.0M (Q2 2023) due to strategic repositioning.
Non-GAAP operating cash burn for H1 2024 was $104.6M vs $136.5M in H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.